About
Ryan Dellinger, PhD is Elysium Health's Vice President of Scientific Affairs, leading product development, intellectual property, scientific collaborations, and clinical trials. He holds a PhD in biochemistry and molecular biology from UC San Diego and a BS in biochemistry from the University of the Pacific. Before Elysium, he worked in pharmacology and chemoprevention research at Penn State and UC Irvine. He is also listed as the contact for TIME-A, Elysium's longitudinal epigenetic-aging study connected to Index.
What to Know
Signature approach
Dellinger sits at the trial-and-publication layer behind Elysium's products. His work connects the supplement portfolio, Index, and TIME-A to study design, scientific collaborations, and peer-reviewed outputs, including Elysium-affiliated work on NRPT and aging-related biomarkers.
What sets them apart
- TIME-A contact. ClinicalTrials.gov lists him as the contact for Elysium's longitudinal epigenetic-aging study.
- Published company science. He appears on Elysium-affiliated papers in BMC Nephrology and Frontiers in Aging.
- Chemoprevention background. Penn State and UC Irvine work gives him a research base before the Elysium chapter.
- Scientific affairs role. He connects product development, IP, collaborations, and trials beyond advisory-only work.
Expertise
Focus areas
Affiliations
Head of Research
Thought Leadership
Publications
- Nicotinamide riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI · BMC Nephrology, 2020
- Nicotinamide riboside and pterostilbene reduces frequency of [...] · Frontiers in Aging, 2026
Other specialists at Elysium Health
Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.